Bio Saga Headlines

Bio Saga

Tuesday, December 27, 2011

Ph.D. position in DRDO @ Ministry of Defence, Government of India

Applications are invited from CSIR qualified candidates (or candidates with DBT/DST/ICMR/INSA funding) for a doctoral position in Defence R&D Organization, Ministry of Defence, Government of India. The doctoral position is in the area of Bioinformatics. The area of research is understanding human acclimatization in extreme environmental conditions.

Applicants should send a cover letter and CV and the names and addresses (including telephone and email) of three referees who are knowledgeable about the candidate's professional qualifications to pkhurana08[at]

Dr. (Mrs.) Pankaj Khurana
Scientist 'C'
Defence Institute of Physiology and Allied Sciences,
Defence R&D Organization,
Lucknow Road,
New Delhi

Tuesday, December 20, 2011

Biotechnopreneur Camps 2012

Gujarat State Biotechnology Mission (GSBTM), Gujarat Venture Finance Limited (GVFL) & Foundation for MSME Clusters (FMC)
along with SkyQuest Technology Consulting Pvt. Ltd. (Knowledge Partner)
Life Sciences | Medical Devices | Biotechnology | Pharmaceuticals
Fostering Technology based Entrepreneurship in Gujarat

The journey of Biopreneur Camps 2011 from Surat, Vallabh Vidyanagar, Baroda and Ahmedabad saw 100 participants at each venue; graced by the presence of eminent guests including Mr. Ketan Patel, MD, Troikaa Pharmaceuticals, Dr. Chandan Chatterjee, Director, The Centre for Entrepreneurship Development (CED), Govt. of Gujarat; Dr. Ravi Dhar, Senior Consultant – Biotechnology Industry Research Assistance Programme (BIRAP) of Dept. of Biotechnology, Govt. of India, Dr. V. S. Patel, Ex-Vice Chancellor, S. P. University and Director, Sophisticated Instrumentation Centre for Applied Research and Testing (SICART) and many more in addition to Shri Mihir Joshi, MD, GVFL; Dr. A. S. Rao, Ex-Sr. Advisor, Dept. of Science & Technology, Govt. of India and currently, also Advisor, FMC and Shri A. K. Saxena IFS, Mission Director, GSBTM, Department of Science & Technology, Govt. of Gujarat.

The programme helped many researchers to turn their science project into business idea and many entrepreneurs to get new ideas.

BiotechnopreneurTM Camps 2012 is a platform for budding entrepreneurs, researchers and students to understand various aspects of biotech entrepreneurship from industry leaders, successful entrepreneurs, representatives of Government and academicians.

Key features of BiotechnopreneurTM Camps 2012:

~         Pitch your Business Idea: Seek assistance at any stage for your technology idea
~         My Story Session: Get inspiration from Successful Biotechnology Entrepreneurs
~         Plenary Sessions
~         Network: Interact and with experts and consultants from diverse fields (Technology, Market, Finance, Policies etc.)


BiotechnopreneurTM team invites you to “PITCH YOUR BUSINESS IDEA” - An opportunity to present your business idea among a panel of technology experts, businessmen and investors. 

Pitch your Business Idea and you will get a chance to seek mentoring & support to start your own biotechnology based business venture.

Business Idea/Concept/Venture in Lifesciences domain
Applicants from the State of Gujarat

Who can apply?
  • Budding Entrepreneurs/Start-ups
  • Innovators planning a venture based on their innovation/s
  • Researchers looking to take their technology to market 
Shortlisted Applicants will get a 15 minute slot to present your business idea at BiotechnopreneurTM Camps 2012 and will be offered support like mentoring, strategic advisory, getting investor-ready, applying for funding.

Ahmedabad | Mehsana| Rajkot | Surat | Vadodara

Documents to be submitted (Only Soft Copy):
  1. Business Idea – Concept note
  2. Anticipated Support  (not more than 200 words)
  3. Detailed profile of Applicant
  4. Scanned Passport size Photograph 
Deadline for Application:
The entries should reach us by email ( latest by 31st December 2011 by 5:00pm

Note:- Subject should be “Pitch Your Business Idea – Biotechnopreneur Camps 2012”

For any further clarification or details, write to Ms. Neha Jhala on

Tuesday, December 13, 2011

Elsevier Acquires Ariadne Genomics

Elsevier, a world-leading provider of scientific, technical, and medical information products and services, announced today the acquisition of the business assets of Ariadne Genomics, a provider of pathway analysis tools and semantic technologies for life science researchers. Ariadne will be integrated with Elsevier's Corporate Markets division.
"Ariadne Genomics' pathway analysis tools and semantic technologies integrate research findings from across multiple content sources providing a deeper understanding of biological pathways and disease progression. Ariadne's products improve research productivity and outcomes for life science researchers by delivering new insights for potential interventions, therapies and cures," said Alexander van Boetzelaer, Managing Director of Elsevier Corporate Markets. "Ariadne brings to Elsevier an information offering in the biology domain and a passionate and dedicated team of life science professionals. Ariadne's team and offerings are a powerful complement to our chemistry, pre-clinical and clinical workflow solutions."
Ariadne's flagship product Pathway Studio is widely used by pharmaceutical, agriculture and academic institutions to provide analyses of molecular pathways and disease progression. Pathway Studio is an integrated data mining and visualization solution that organizes relevant facts and relationships from large document collections of genes, proteins, cell processes and diseases. The tool, powered by Ariadne's MedScan® technology, enables visualization of biological relationships spanning biomedical literature and supports the interpretation of experimental results utilizing domain-specific ontologies, taxonomies and dictionaries.
"As a customer of both providers, I am excited to learn that Ariadne Genomics and Elsevier have joined," said Dr. Jonathan Usuka, Director of Global Business Planning at Celgene, a multinational biopharmaceutical company. "Pathway Studio provides essential support to our immunological studies. As part of Elsevier, there is the potential to deliver even more value to our researchers."
Ariadne's CEO, Ilya Mazo, said of the acquisition, "With our integration into Elsevier, we look forward to strengthening our ability to serve biological researchers in scientific communities through further development of Pathway Studio, fortified with Elsevier's content, and complementing Elsevier's leadership role across biomedical disciplines."
Ariadne is headquartered in Rockville, Maryland. Financial details of the acquisition are not being disclosed.

GN Ramachandran Fellowships in the field of computational biology

December 12, 2011

Applications are invited for the GN Ramachandran Fellowships recently instituted by the CCBB, DBT-COE, JNU to encourage young scholars to work in the interdisciplinary research in the field of computational biology. The fellowship is meant for brilliant scientists and engineers from all over the world to take up scientific research positions at SCIS, JNU.

SCOPE : Computational Biology & Data Mining.

QUALIFICATION & BACKGROUND:i) The fellowship is open to brilliant scientists and engineers who are below the age of 35 years .
ii) The applicant should possess a Ph.D. in Science/Engineering and have adequate professional experience.
iii) These Fellowships are very selective and only those who have a proven/outstanding track-record as evident from their research publications and recognitions would be eligible.

ELIGIBILITY FOR JUNIOR FELLOW :1. Ph.D. in any branch of natural sciences.
2. At least 2 years Post-Doc experience in theoretical/computational/quantitative sciences.
3. Preferable experience in the area of simulations, large scale data analysis, statistical modeling.

DURATION : The duration of the fellowship will be for three years or until the project (DBT-COE at JNU) granted, whichever comes first. Every year a report will be submitted for successful progress.

  • The value of the fellowship will be Rs.40,000/- per month (consolidated)for Junior fellowship.
  • School will provide the necessary R&D, administrative and basic infrastructural support to facilitate research. Please see the website :
  • The GN Ramachandran Fellows will be eligible & encouraged for receiving regular research grants through the extramural funding schemes of various S&T agencies of the Government of India.
  • The scientists will be working at CCBB, SCIS, JNU and collaboration with the members of SCIS as well as outside the school is encouraged.

  • The availability of Fellowships will be through application and forms are available through CCBB. The applicant may apply through the form duly filled up and by email.
  • Selection of Fellows will be made at least once/year by an empowered Search-cum-Selection Committee specially appointed for the purpose.
All applications may be sent to :
The Coordinator
Centre for Computational Biology and Bioinformatics
School of Computational and Integrative Sciences
Hall No.6, Lecture Hall Complex
Jawaharlal Nehru University New Delhi – 110 067.
Email : Tel.: (011) 2674 1517
Last Date for application : Dec 25th.2011

Monday, December 12, 2011

Inherit the RNA

A new study in Cell shows that C. elegans doesn't need DNA or even epigenetics to pass traits down through the generations, says 80beats' Veronique Greenwood. Some worms can use RNA to fight off viruses and that these molecules — and the ability to fight the virus — can be passed on for more than 100 generations, she adds. The researchers engineered worms that didn't have the genes to make the RNAs necessary to fight a virus, and then bred them with worms that did have these genes for several generations. Some of the resulting offspring had ancestors with the virus-fighting molecules, but didn't have the genes themselves. But when they observed the worms under the microscope, Greenwood says, the researchers saw that the gene-less worms were still fighting off the virus like their grandparents had. The researchers speculate that "the RNA molecules made by the original worms in response to a virus attack were floating around in the cytoplasm of the eggs and sperm that became their offspring," Greenwood says.

Inherit the RNA | The Daily Scan | GenomeWeb

Tuesday, November 8, 2011

PerkinElmer Completes $600M Caliper Acquisition

PerkinElmer is pleased to announce that today it completed the acquisition of Caliper Life Sciences, an exciting milestone in PerkinElmer’s evolution. The purchase, announced in September.

Bringing Caliper into PerkinElmer will significantly strengthen leadership position in the growing area of personalized medicine, providing pharmaceutical companies and clinicians with the tools and knowledge they need to enable individualized diagnoses and treatments. PKI's work moving ahead in this emerging field will be made possible by an outstanding team of people from Caliper and PerkinElmer collaborating together to leverage the combined power of their knowledge and expertise to deliver insight-driven innovations.

Bio-discovery and Caliper will combine to form PerkinElmer’s new Life Sciences & Technology (LST) Strategic Business Element (SBE). In a statement today, Robert Friel, chairman and CEO of PerkinElmer, said that he is confident that joining together these two organizations will create powerful momentum and inspire new ways to develop targeted solutions to meet customer needs across the in vitro to in vivo value chain, from disease research to drug discovery to clinical applications. It will also enable PKI to expand its offerings across our biomedical, diagnostics, environmental and food safety end markets.

Kevin Hrusovsky, who had been Caliper's CEO, will now take on the role of president of life sciences and technology for PerkinElmer, where he will head a newly combined $500 million business, "which integrates the former Caliper organization with PerkinElmer's existing research business," Friel said.

Monday, November 7, 2011

PerkinElmer Announces Financial Results for the Third Quarter of 2011

PerkinElmer reported after the close of the market on Thursday that revenues in the third quarter rose 8 percent year over year, but it missed analyst estimates on the top line.
Total revenues in the quarter ended Oct. 2 rose to $453.7 million, compared to $419.1 million a year ago but fell short of Wall Street estimates of $469.6 million. On an organic basis, revenues were up 4 percent year over year.
The firm has made a number of purchases throughout 2011 and in the quarter those acquisitions contributed more than $20 million to the top line, CFO Frank Wilson said on a conference call after the release of the company's earnings results.
The Human Health segment grew revenues to $207.4 million, up 7 percent from $194.5 million a year ago, while Environmental Health climbed to $246.3 million, a 10 percent increase from $224.6 million a year ago.
On the conference call, Chairman and CEO Robert Friel said that during the quarter, growth was seen across all major geographies and most end markets.
The Waltham, Mass.-based company grew sales in Europe in the low-single digits. While 30 percent of the company's business is tied to Europe, Friel said that much of that is in end markets that will not be significantly impacted by the challenging macroeconomic environment there. Only about 5 percent of total revenues is tied directly to government spending that could be exposed to austerity measures in Europe, he said.
The US grew in the mid-single digits, and while macro conditions will be challenging, he said that the company is seeing improving birth rates, which could benefit its newborn screening business, and continued demand for environmental and safety products.
The US academic/government end market represents about 10 percent of revenues, with a large portion of PerkinElmer's exposure in that market in the newborn screening space, which is primarily state funded. Friel said that as long as he's been with the company, he has never seen a decline in funding for newborn screening from states, and in the third quarter, PerkinElmer's newborn screening business grew.
In developing geographies, business rose in the double-digits, and PerkinElmer expects that to continue, Friel said

JGI's Community Sequencing Program - Plans for 2012

The Department of Energy's Joint Genome Institute has chosen 41 research projects out of 152 applicants to use its sequencing services under its 2012 Community Sequencing Program, JGI said Thursday.
Researchers for this year's CSP program, which provides the scientific community with access to JGI's high-throughput sequencing technologies, proposed projects to study plant-microbe interactions, how microbes are involved in carbon capture and greenhouse gas emission, and metagenomics.
“These selections truly take advantage of the DOE JGI’s massive-scale sequencing and data analysis capabilities,” DOE JGI Director Eddy Rubin said in a statement.  “The projects span the globe and the unexplored branches of the tree of life, and promise to yield a better understanding of the interplay between climate, ecosystem, and organism.  Still other projects are targeting improvements in biofuel feedstock production, focusing on the potential of microorganisms to improve feedstock growth and prevent devastating diseases that hinder yields.”
The winning projects involve a wide range of microbial sequence-based research efforts focused on DOE JGI's core mission areas.
University of North Carolina at Chapel Hill Principal Investigator Jeff Dangl and his team plan to study the rhizosphere, the region where microbes in the soil colonize and interact with plant roots, and how it is involved in plant growth and productivity. Dangl's lab will focus on the microbiomes of maize, Arabadopsis, and a mustard relative, among others.
Another project, headed by Professor Jill Banfield at the University of California, Berkeley, plans to study genomes from microbial communities located at a DOE bioremediation research site in Colorado. The team seeks to identify novel rare microbes that might be useful for environmental cleanup of metals and radionuclides.
A group led by University of Vienna Investigator Michael Pester will study the greenhouse gas emissions of microbial communities that reside in peatlands, which are known carbon sinks that contain methane-producing microorganisms.
Another project, proposed by US Department of Agriculture Research Molecular Biologist Jo Anne Crouch, will study species of a grass-infecting fungus in order to find ways to protect potential bioenergy feedstocks from diseases caused by fungal pathogens.

A complete list of the 41 CSP 2012 sequencing projects is available on JGI's website.

Wednesday, November 2, 2011

Toronto Genomics Center Lands $5M from Genome Canada

The Centre for Applied Genomics (TCAG) at the Hospital for Sick Children in Toronto has reeled in C$5.1 million (US$5 million) from the Ontario Genomics Institute to support its operations, OGI said today.
TCAG provides a range of core services including gene and genome sequencing; microarrays and genotyping; cytogenomics and biobanking; and statistical and informational services.
The two years of funding was awarded under the Genome Canada Science and Technology Innovation Centre Competition.
TCAG was founded in 1998 and it provides research support to labs involved in a wide array of genomic disciplines including human health, agriculture, and plant and animal studies.

Monday, October 24, 2011

Ph.D. Student position Neuroscience at Bernstein Center Freiburg Germany

The role of dichotomous properties of D1 and D2 medium spiny neurons for the dynamics and function of striatum
The striatum is the main input station of the basal ganglia and is strongly associated with motor and cognitive functions. It is a recurrently connected network of GABAergic medium spiny neurons (MSNs), which receive strong feedforward inhibition from the fast spiking interneurons and massive excitatory afferents from various regions of the neocortex via the cortico-striatal projection neurons. Interestingly, neighboring MSNs do not share their presynaptic inputs. Recently, we have shown that this special structure of cortico-striatal projections provides optimal conditions for the representation of cortical inputs in the striatum.
The MSN population in the striatum can be segregated into two types: D1 type MSNs project to the globus palidus external (indirect path) and D2 MSNs project to the globus palidus internal (direct path). Recent experiments have revealed a great degree of differences between D1 and D2 MSNs in terms of their morphology, integration properties, synaptic dynamics and connectivity.

This project requires one to understand the consequences of these different neuronal, synaptic, and network properties of the two types of MSNs for the striatal activity dynamics and representation of cortical inputs. To address this question we will use a combined experimental and theoretical approach. Relevant experiments will be conducted in the lab of Prof. Gilad Silberberg (Karolinska Institute, Stockholm, Sweden). Analysis of experimental data and development of network models will be done in the lab of Dr. Arvind Kumar and Prof. Ad Aertsen (Bernstein Center Freiburg).
Looking for candidates with a strong background in Physics or Electrical Engineering and a genuine interest in Neuroscience, who are interested in interdisciplinary research and are willing to learn and perform neurophysiology in animal experiments.
Please apply here:
Closing date: 2011-11-30

Tuesday, October 11, 2011

Study of Ethics of Sharing DNA Information

Inching toward the Dawn of the GATTACA era!, making up history as we went along. 

A group of researchers will use a $2.5 million federal grant to study the ethical and legal implications of providing genetic research results to the relatives of people who donated samples to biobanks, Mayo Clinic said today.
The grant from the National Cancer Institute and the National Human Genome Research Institute will fund researchers at Mayo, the University of California, San Francisco, and the University of Minnesota who will study what families prefer, will analyze the legal and ethical issues, and propose recommendations for best practices policies.
"Substantial debate surrounds the question of whether researchers have an ethical obligation to return individual research results to genetic relatives of patients, especially when the patient has died, and incidental findings have potential health or reproductive importance for kin," Gloria Petersen, the Purvis and Roberta Tabor Professor at Mayo Clinic, said in a statement.
"Establishing best practices for navigating this issue is becoming increasingly important as biobanks all over the world are archiving genetic data and making those data available for secondary analyses, often years after the DNA was donated," Petersen said.
Petersen said that genetic information from biosamples can be used for research purposes for a very long time, even long after the donor is deceased, and can provide valuable information to the rest of their families.
"This genetic information could actually have tremendous relevance for their children, and their brothers and sisters," she said. "We seek to understand how best to tell the family members who could be affected by research findings when the family members themselves were not the research subject – the person who is now deceased is."
Petersen said the researchers plan to use surveys and interviews with people who may be affected by such policies, analyze the results, discuss the ethical and legal issues, and then will develop the recommendations within the next three to four years.

Tuesday, September 27, 2011

Rhythmic Energy my band on Air 94.3 FM RadioOne Bangalore

Look for RE on Air 94.3 FM Bangalore

In case you face any bandwidth issues try this one!

Tuesday, September 20, 2011

Algorithm tailored for short-read data from single cells that improves assembly


Whole genome amplification by the multiple displacement amplification (MDA) method allows sequencing of DNA from single cells of bacteria that cannot be cultured. Assembling a genome is challenging, however, because MDA generates highly nonuniform coverage of the genome. Here we describe an algorithm tailored for short-read data from single cells that improves assembly through the use of a progressively increasing coverage cutoff. Assembly of reads from single Escherichia coli and Staphylococcus aureus cells captures >91% of genes within contigs, approaching the 95% captured from an assembly based on many E. coli cells. We apply this method to assemble a genome from a single cell of an uncultivated SAR324 clade of Deltaproteobacteria, a cosmopolitan bacterial lineage in the global ocean. Metabolic reconstruction suggests that SAR324 is aerobic, motile and chemotaxic. Our approach enables acquisition of genome assemblies for individual uncultivated bacteria using only short reads, providing cell-specific genetic information absent from metagenomic studies.

Figures at a glance

Thursday, September 8, 2011

PerkinElmer to Acquire Caliper Life Sciences for Approximately $600 Million

PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it has signed a definitive agreement to acquire Caliper Life Sciences, Inc., a Hopkinton, Massachusetts-based leader in imaging and detection solutions for life sciences research, diagnostics and environmental markets, for $10.50 per share, for a total net purchase price of approximately $600 million in cash.
Robert F. Friel, chairman and chief executive officer, PerkinElmer, said, "The acquisition of Caliper Life Sciences brings innovative molecular imaging and detection technologies to our portfolio, complementing our world-leading offerings in life science, diagnostics, environmental and food markets."
Friel added, "The R&D, application expertise, and intellectual property of the combined organization will provide our customers with enhanced knowledge and services and a strong pipeline of innovation. Additionally, the proven leadership and talent of the Caliper team will be a strong addition to our organization."
The combined technology platforms will expand PerkinElmer's deep portfolio of solutions and services for global customers.

Thursday, September 1, 2011

International Conference on Perspective of Cell Signaling and Molecular Medicine

2nd International Conference on Perspective of Cell Signaling and Molecular Medicine  8 to 11 January, 2012 Organised by Bose Institute, Kolkata
Instructions for Submission of Abstract :
1. Only abstracts containing new results will be accepted. Abstracts should clearly and adequately describe the objectives and results of the research. All abstracts must be submitted in English. All abstracts must be accompanied by a completed Conference Registration Form made out in the name of one of the Authors.
a. Each abstract should include a title (in capital letters), name(s) of all authors (underline the presenting author), affiliation and email address.
b. Type entire abstract single-spaced; typing area: width 12.0 cm (4.7 inches), height 24 cm (9.4 inches).
c. Careful typing and proof-reading are essential.
Registration :
  • Registration fees : Rs. 4,000/ (Scientist); Rs. 2,500/ (Students including post-docs)
  • Late Registration fees : Rs. 5,000/ and Rs. 3,500/ respectively
  • Accompanying persons : Rs. 3,000/ and Rs. 2,000/ respectively
  • $300  (Foreign participants); $200 (Foreign students)
Contact :Prof. Parimal C. Sen
International Conference on Perspective of Cell Signaling and Molecular Medicine
Bose Institute,
P-1/12 CIT Scheme VII M,
Kolkata-700 054, India.
Tel: +91-33-2569-3222; +91 9433012797 (Cellular)
Fax:  +91-33-2355-3886
E-mail: |
Dead-line for Registration : November 15, 2011

Life Science and Informatics

What is this?
is this a new industry?
or a old wine in a new bottle?

Well Life Sciences and Informatics can be anything form computational biology, all omes and omics, core bioinformatics to curation and literature mining, database creation, in the area of biology, chemistry , bio-chem space.

There are number of companies in India and bangalore is the forefront as a major bio-cluster with 20 to 30 companies in this sphere.

now how good are these companies doing?
how good are they in terms of the international markets and how profitable is their business?
what do they do?
their clients?

These are some interesting things that could be discussed in this blog page...

Tag It